---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-096701"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2022-09-01T23:59:59+00:00"
generated_at: "2026-06-23T17:13:43.239626+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Court rules Liquidia's Yutrepia infringes United Therapeutics patent; injunction expected through 2027

## Summary
- District Court finds Liquidia would induce infringement of '793 patent claims; claims not invalid.
- Court expects to enter injunction barring FDA approval of Yutrepia until '793 patent expires May 14, 2027.
- Court found Yutrepia would infringe '066 patent claims but held those claims invalid; United Therapeutics evaluating appeal.
- PTAB recently invalidated '793 patent in IPR; United Therapeutics seeks rehearing and plans appeal; patent remains valid during appeals.
- Both parties have right to appeal; United Therapeutics will vigorously defend IP.

## SEC filing metadata
- accession: 0001104659-22-096701
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2022-09-01T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000110465922096701/0001104659-22-096701-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000110465922096701/tm2224949d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-096701
- JSON: https://secwatch.observer/filing/0001104659-22-096701.json
- Plain text: https://secwatch.observer/filing/0001104659-22-096701.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.